METASTATIC BREAST CANCER

This Phase 2 trial tested whether disulfiram (Antabuse), a drug used for alcoholism, combined with copper supplements could help people with metastatic breast cancer who had run out of standard options. Only 9 patients took part, and researchers measured tumor response and surviv…

This study compares a new formulation of the chemotherapy drug doxorubicin (Doxopeg) to the standard version (Caelyx) in people with advanced ovarian cancer or metastatic breast cancer. The goal is to see if the two drugs are absorbed and processed by the body in the same way. Pa…

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This early-phase trial tested whether using mathematical models to schedule chemotherapy drugs docetaxel and epirubicin could reduce severe side effects in 17 patients with metastatic breast cancer. The goal was to find the safest dose and schedule while still giving six cycles o…

This early-phase study tested a new drug called ONO-4578 combined with standard hormone therapy and targeted drugs (letrozole plus palbociclib or abemaciclib) in 46 postmenopausal women with advanced or recurrent hormone receptor-positive, HER2-negative breast cancer. The main go…

This phase 2 study tested a drug called patritumab deruxtecan in 121 people with advanced or metastatic breast cancer. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The main goal was to see how many patients had their tumors shr…

This early-phase trial tested a combination of four therapies to see if they could safely boost the immune system to fight cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head & neck cancer received low-dose radiation and two immune-boosting drugs inje…

This phase 2 trial tested a drug called patritumab deruxtecan (HER3-DXd) in 63 patients with breast cancer, lung cancer, or other solid tumors that had spread to the brain or the lining of the brain and spinal cord. The drug is designed to seek out and destroy cancer cells carryi…

This study tested a new drug called taselisib combined with standard anti-HER2 therapies in 68 people with advanced HER2+ breast cancer. The goal was to find the safest dose and see if the combination could shrink tumors or slow the disease. While not a cure, the approach aims to…

This early-phase trial tested a personalized cancer vaccine (SV-BR-1-GM) combined with an immunotherapy drug (retifanlimab) in 36 people with advanced breast cancer that had stopped responding to standard treatments. The vaccine is made from the patient's own tumor cells and aims…

This study tested a new two-drug combination (samuraciclib and elacestrant) in 49 adults with a common type of advanced breast cancer (HR+/HER2-). The goal was to find a safe dose and see if it can slow the cancer's growth. Participants had already tried other treatments and thei…

This early-phase trial tested a new drug, ipatasertib, added to two existing breast cancer medicines (trastuzumab and pertuzumab) in 17 people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation). The main goal was to find the safest dose…

This study looked at whether a test called RAD51-foci can predict how well the drug olaparib works in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). About 65 participants received olaparib, and researcher…

This phase II trial tested the drug alisertib, alone or combined with fulvestrant, in 96 postmenopausal women with advanced breast cancer that no longer responds to hormone therapy. Alisertib blocks enzymes that help cancer cells grow, while fulvestrant blocks estrogen. The goal …

This study looked at whether adding focused radiation to the cancer spots (metastases) can help people with breast cancer that has spread to a few places (up to 5 spots). 87 participants received either standard drug therapy alone or standard therapy plus radiation. The goal was …

This Phase 3 trial compared the pill olaparib to standard chemotherapy in 302 people with metastatic breast cancer who have inherited BRCA1 or BRCA2 mutations. The goal was to see if olaparib could slow cancer growth better than chemo. Participants took olaparib twice daily or re…

This study tested a combination of two drugs, palbociclib and tamoxifen, as the first treatment for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). The goal was to see how long the cancer could be kept from growing. 49 participants took both pil…

This study tested a new bone graft material, ZetaMet, in 10 women with breast cancer that spread to their spine, causing bone defects. The graft was implanted into the damaged vertebra to see if it could safely stabilize the spine and reduce pain. The main goals were to track com…

This early-phase trial tested a combination of three drugs—olaparib, palbociclib, and fulvestrant—in 9 people with BRCA-mutated, hormone-positive, HER2-negative metastatic breast cancer. The main goal was to see if the combination is safe. Researchers also looked at how long the …

This study tested whether adding the experimental drug samuraciclib to standard hormone therapy (fulvestrant) works better than fulvestrant alone for people with advanced HR+/HER2- breast cancer. The trial enrolled 60 adults whose cancer had worsened despite prior treatment. Rese…

This early-phase study tested whether combining stereotactic radiosurgery (precise radiation) with the immunotherapy drug nivolumab (Opdivo) is safe and can shrink tumors in people with breast cancer that has spread to the brain. Fourteen participants received the combination. Th…

This early-phase trial tested a new way to treat advanced cancers that have spread. It combined a special type of radiation with two immunotherapy drugs (MEDI4736 and tremelimumab) to see if the combination is safe and tolerable. The study included 53 adults with advanced melanom…

This study looked at 155 people with metastatic breast cancer whose original tumors were HER2-negative. Researchers checked their blood for HER2-positive cancer cells. Those who had them received the drug T-DM1, which delivers chemotherapy directly to HER2-positive cells. The goa…

This study tested a new way to give the drug trastuzumab (Herceptin) to women with HER2-positive breast cancer that had spread to the lining of the brain. Instead of through a vein, the drug was injected directly into the spinal fluid via a lumbar puncture or a special reservoir.…

This study tested a new strategy for people with a common type of advanced breast cancer (ER+, HER2-). It used a blood test to look for a gene change (ESR1 mutation) that can make cancer stop responding to the first hormone therapy. When the mutation appeared, some patients switc…

This study looked at combining the drug abemaciclib with standard hormone therapy as a first treatment for women with metastatic breast cancer that has spread to organs or has a high tumor burden. The goal was to see how many patients' tumors shrank or disappeared. The study enro…

This completed Phase 2 trial tested whether adding atorvastatin (a cholesterol-lowering drug) to standard hormone therapy (letrozole or fulvestrant) could improve outcomes in 126 women with advanced, hormone-receptor-positive breast cancer. The main goal was to see if the combina…

This pilot study tested a new radioactive tracer called 89Zr-DFO*-trastuzumab in 6 people with HER2-positive breast or gastric cancer. The tracer is designed to attach to HER2 proteins on cancer cells and show up on PET scans. Participants received one injection and had up to 4 P…

This study tested a simple questionnaire called the Values Assessment Tool to help women with metastatic breast cancer and their caregivers talk about what matters most to them with their doctors. The goal was to see if using the tool reduces confusion about treatment choices and…

This study looked at 8 adults with metastatic breast cancer who were starting the drug alpelisib. Alpelisib often causes high blood sugar, so researchers used a continuous glucose monitor (a small sensor worn on the arm) to track glucose levels day and night for at least 3 months…

This study looked at whether a 6-month physical activity program using a fitness tracker could help women with metastatic breast cancer feel better and less tired. 124 women with hormone receptor-positive, HER2-negative metastatic breast cancer who were starting chemotherapy took…

This study tested whether an online exercise and education program could help cancer patients and survivors feel better during the COVID-19 pandemic. Thirty adults with metastatic breast or gynecological cancer, or breast cancer survivors, took part. The program aimed to reduce f…

This pilot study tested a smartphone app that lets breast cancer patients on oral chemotherapy report side effects and get basic advice. Hospital pharmacists were alerted when needed. The goal was to see if the app could improve monitoring and reduce phone calls. Only 28 patients…

This study tested whether group-based cancer rehabilitation could work when done virtually instead of in person for people with advanced breast or colorectal cancer. 111 participants were offered either in-person or online sessions to see which was more practical and acceptable. …

This completed trial tested a web-based remote monitoring platform called CONTINUUM+ CONNECT in 411 adults with metastatic breast, lung, colorectal, or prostate cancer. Patients used the platform to report symptoms and receive alerts, aiming to improve their physical health and q…

This study tested whether telemedicine and connected watches can help monitor symptoms and improve quality of life for women with advanced breast cancer who live far from their cancer center. Fifteen patients reported symptoms weekly on a tablet, while a smartwatch tracked their …

This study tested a therapy called Managing Cancer and Living Meaningfully (CALM) to see if it helps people with brain cancer feel less distressed. 60 adults with brain tumors or brain metastases who had high depression or death anxiety took part. The study measured how many peop…

This study looks at medical records from across Europe to see how well a drug combination (palbociclib plus an aromatase inhibitor) works as a first treatment for people with a common type of advanced breast cancer (HR+/HER2-). Researchers want to understand how long the treatmen…

This study looks at how the adrenal glands work in people who are critically ill, such as those with sepsis. Adrenal insufficiency may affect up to 77% of ICU patients, but current tests are not reliable. Researchers will measure hormone levels in 225 participants, including heal…

This study explored whether a simple blood test measuring the neutrophil-to-lymphocyte ratio (NLR) can help predict how well women with advanced breast cancer respond to a common treatment (CDK4/6 inhibitors plus hormone therapy). Researchers followed 165 patients starting this t…

This study looked at 185 people with a common type of advanced breast cancer (HR+/HER2-) in Africa and the Middle East who were starting treatment with palbociclib combined with hormone therapy. Researchers tracked how long the cancer stayed under control and how patients felt ov…

This study examined blood samples from 49 women with metastatic breast cancer to find genetic markers that predict side effects from trastuzumab (Herceptin). The goal was to understand why some patients experience heart or allergic reactions. It did not test a new treatment, but …

This study looked at whether information from routine medical records (real-world data) can produce the same results as a carefully controlled clinical trial called MONALEESA-2 for advanced breast cancer. Researchers analyzed data from over 2,400 patients to see if they could rel…

This completed study looked at whether information from routine medical records can produce the same results as a gold-standard clinical trial. Researchers analyzed data from 3,883 women with advanced breast cancer to see if real-world analyses could match the findings of the MON…

This study examined whether specific gene variations influence how well metastatic breast cancer patients respond to chemotherapy with or without the drug bevacizumab. Researchers enrolled 307 women from Italy to compare outcomes and analyze genetic interactions. The goal was to …

This completed study looked at whether a deficiency in the DPD enzyme can predict severe side effects from the chemotherapy drug capecitabine in women with metastatic breast cancer. Researchers analyzed blood samples from 303 participants to see if genetic differences could help …

This study aims to develop and validate a scoring system to identify which patients with metastatic breast cancer are likely to live longer with third-line chemotherapy. Researchers will collect clinical, histological, and biological data from 267 women starting a third line of t…

This completed study from the University of Alabama at Birmingham involved 200 women with metastatic or early-stage breast cancer. Researchers conducted interviews and focus groups with patients, nurses, and doctors to understand how treatment decisions are made, including the op…

This study interviewed 48 adults with HR+/HER2- metastatic breast cancer who had taken capivasertib + fulvestrant for at least one week. The goal was to learn about their attitudes, experiences, and any side effects related to the treatment schedule. No new drugs were given; it w…

This study looked at how well anti-HER2 drugs work in Egyptian women with HER2-positive breast cancer. Researchers followed 80 patients who received either one drug (trastuzumab) or a combination (trastuzumab plus pertuzumab or lapatinib) as part of their regular care. The goal w…

This completed study looked at 559 adults in Israel with metastatic breast cancer who were prescribed palbociclib (Ibrance) as part of their treatment. Researchers tracked how the drug was used in everyday practice, including doses, combinations with other treatments, and how lon…

This completed study looked at records from over 20,000 women with metastatic breast cancer in France. Researchers wanted to see if earlier measures of treatment success, like progression-free survival, could reliably predict overall survival. By comparing real-world data to clin…

This study looked at whether measuring circulating tumor cells (CTCs) in the blood can help doctors decide when to switch chemotherapy for women with metastatic breast cancer that has worsened after two prior treatments. The trial involved 265 women and compared standard care wit…

This study looked at 60 people with metastatic breast cancer to find out whether certain cells in their blood (called DP-circulating cells) come from the tumor. Researchers took a blood sample before starting treatment and checked tumor samples. The goal was to better understand …

This completed study observed 22 adults with HER2-positive or HER2-low metastatic breast cancer who were taking trastuzumab deruxtecan (Enhertu) as part of routine care. Researchers tracked how many patients stopped treatment early or needed dose changes, and why. The goal is to …

This study looked at whether a blood test called DiviTum-TKa can help doctors check if patients with metastatic breast cancer are taking their CDK4/6 inhibitor medication correctly and if other drugs are interfering. The test measures a marker of cell growth to see if the treatme…